Genome-based pharmacogenetics and the pharmaceutical industry

Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to identify patterns of susceptibility genes for common diseases as well as genetic risk/efficacy factors that are related to the effects of drugs.

[1]  R. Havlik,et al.  Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study. , 2000, Clinical chemistry.

[2]  J A Lewis,et al.  New active substances authorized in the United Kingdom between 1972 and 1994. , 1998, British journal of clinical pharmacology.

[3]  A. Roses,et al.  Pharmacogenetics place in modern medical science and practice. , 2002, Life sciences.

[4]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[5]  S. Hetherington,et al.  Risk factor analysis of hypersensitivity reactions to abacavir. , 2002, Clinical therapeutics.

[6]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[7]  A. Roses,et al.  Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. , 2002, Genomics.

[8]  S. Liu-Cordero.  Patterns of linkage disequilibrium in the human genome , 2002 .

[9]  M. Boyce-Jacino,et al.  A SNPshot: pharmacogenetics and the future of drug therapy. , 2000, Trends in biotechnology.

[10]  L J Lesko,et al.  Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[11]  A. Roses,et al.  Pharmacogenetics and future drug development and delivery , 2000, The Lancet.

[12]  J. Kahn,et al.  Pharmacogenetic challenges for the health care system. , 2002, Health affairs.

[13]  G. H. Bush,et al.  Pharmacogenetics , 1968 .

[14]  G. Tsongalis,et al.  Pharmacogenomics: will it change the field of medicine? , 2001, Clinica chimica acta; international journal of clinical chemistry.

[15]  R C Elston,et al.  Testing drug response in the presence of genetic information: sampling issues for clinical trials. , 2000, Pharmacogenetics.

[16]  A. Burden,et al.  The genetics of allergic contact hypersensitivity to nickel , 1999, Contact dermatitis.

[17]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[18]  P. Reiss,et al.  Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.

[19]  A. Motulsky.  Pharmacogenetics and ecogenetics in 1991. , 1991, Pharmacogenetics.

[20]  Sinead B. O'Leary,et al.  Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease , 2001, Nature Genetics.

[21]  P. R. Boyd,et al.  Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. , 2001, Genomics.

[22]  A. Califano,et al.  Pharmacogenetics: Ethical Issues and Policy Options , 2002, Kennedy Institute of Ethics journal.

[23]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[24]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[25]  J. Gilbert,et al.  SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. , 2000, American journal of human genetics.

[26]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[27]  M. Pirmohamed,et al.  Toxicogenetics in drug development. , 2001, Toxicology letters.

[28]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[29]  E Lai,et al.  A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. , 1998, Genomics.

[30]  W. Evans,et al.  Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.

[31]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[32]  A. Motulsky.  Pharmacogenetics and Ecogenetics , 1978 .

[33]  Munir Pirmohamed,et al.  Fortnightly review: Adverse drug reactions , 1998 .

[34]  Yaakov Stern,et al.  The APOE-∊4 Allele and the Risk of Alzheimer Disease Among African Americans, Whites, and Hispanics , 1998 .

[35]  P. Bosma,et al.  Sequence of exons and the flanking regions of human bilirubin‐UDP‐glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler‐Najjar syndrome, type I , 1992, Hepatology.

[36]  H. Keino,et al.  Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome , 1995, The Lancet.

[37]  J. Kurth.  Pharmacogenomics: Future Promise of a Tool for Identifying Patients at Risk , 2000 .

[38]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[39]  M Pirmohamed,et al.  Genetic susceptibility to adverse drug reactions. , 2001, Trends in pharmacological sciences.

[40]  M. I. Ngelman-Sundber.  Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001 .

[41]  J. Witte,et al.  Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial. , 2000, Controlled clinical trials.

[42]  M. Pirmohamed,et al.  ADVERSE DRUG REACTIONS , 1976, BMJ.

[43]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[44]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[45]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[46]  Robert C Green,et al.  Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. , 2002, Archives of neurology.

[47]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[48]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[49]  J. Gilbert,et al.  Analysis of association at single nucleotide polymorphisms in the APOE region. , 2000, Genomics.